Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st ...
23 Avril 2018 - 2:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, announced that two scientific abstracts
have been accepted for presentation at the 21st Annual Meeting of
the American Society of Gene and Cell Therapy (ASGCT), taking place
May 16-19, 2018, in Chicago.
The first presentation will share information relating to
Intellia’s lead in vivo program, for transthyretin amyloidosis. The
data being presented include results from an ongoing collaboration
with researchers at the University of Porto in Portugal. The second
presentation will focus on Intellia’s ongoing research
collaboration with IRCCS Ospedale San Raffaele in Italy to develop
CRISPR-edited, T-cell therapies to address hard-to-treat cancers.
Intellia will also participate in an education session on RNA
therapeutics.
Details of Intellia’s presentations are as follows:
- “Rescue of Amyloid Deposition Phenotype after
Single-Treatment CRISPR/Cas9 Gene Editing in a Humanized Mouse
Model of TTR Amyloidosis”Session:
Neurologic Diseases (Including Ophthalmic and Auditory Diseases)
ISession date/time: Wed., May 16, 2018, 5:30-7:30
p.m. CTLocation: Stevens Salon C, D
- “Hunting WT1-Specific T-Cell Receptors for TCR Gene
Editing for Acute Myeloid
Leukemia”Session: Cancer – Immunotherapy,
Cancer Vaccines ISession date/time: Wed., May 16,
2018, 5:30-7:30 p.m. CTLocation: Stevens Salon C,
D
- “Lipid Nanoparticle-Based RNA Delivery: At the
Intersection of Chemistry and
Immunology”Presenter: Jonathan Finn,
Ph.D., executive director, Platform
BiologySession: Education Session 401 – RNA
TherapeuticsPresentation date/time: Sat., May 19,
2018, 9-9:30 a.m. CTLocation: Salon A-1
In addition, the following Intellia collaborators will highlight
aspects of their research efforts with the Company:
- “Clinical Gene Editing
Programs”Presenter: Beverly Davidson,
Ph.D., chief scientific strategy officer, Children's Hospital of
Philadelphia (CHOP); director, Raymond G. Perelman Center for
Cellular and Molecular Therapeutics, CHOP; Arthur V. Meigs Chair in
Pediatrics, CHOP; and professor, Pathology and Laboratory Medicine,
Perelman School of Medicine, University of
PennsylvaniaSession: Pre-Meeting Program – Gene
Editing WorkshopPresentation date/time: Tue., May
15, 11 a.m.-12 p.m. CTLocation: Continental B
- “TCR Gene Transfer and TCR Gene
Editing”Presenter: Chiara Bonini, M.D.,
Ph.D., full professor, Università Vita-Salute San Raffaele; deputy
director, Division of Immunology, Transplantation and Infectious
Diseases; and head, Experimental Hematology Unit, Ospedale San
Raffaele, ItalySession: 100 Immune Responses to
Cell and Gene Therapies, Mechanisms, Biomarkers and Therapeutic
InterventionsPresentation date/time: Wed., May 16,
2018, 8-8:30 a.m. CTLocation: International
Ballroom North
Abstracts will become available on the ASGCT website on Mon.,
April 30th, at 11 a.m. CT.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, curative therapeutics
using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. The combination of deep scientific, technical and
clinical development experience, along with its leading
intellectual property portfolio, puts Intellia in a unique position
to unlock broad therapeutic applications of the CRISPR/Cas9
technology and create a new class of therapeutic products. Learn
more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com;
follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Intellia within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding our
ability to advance and expand the CRISPR/Cas9 technology to develop
into human therapeutic products, as well as our CRISPR/Cas9
intellectual property portfolio; our ability to achieve stable or
effective genome editing with a single treatment dose; the
potential timing and advancement of our preclinical studies,
including continuing non-human primate studies, and clinical
trials; our ability to replicate results achieved in our
preclinical studies in any future studies, including human clinical
trials; the potential development of ex vivo cell therapeutics of
all types using CRISPR/Cas9 technology; our ability to commence
IND-enabling studies of a lead TTR development candidate by
mid-2018 and subsequently submitting an Investigational New Drug
application by the second half of 2019 that will be accepted by the
regulatory agencies; our intent to present additional data for
organs beyond the liver, additional insertion/repair data, and
preclinical data in support of our first ex vivo programs on
immuno-oncology and autoimmune/inflammation indications during
2018; our ability to nominate a development candidate for a second
indication by late 2018; the intellectual property position and
strategy of Intellia’s licensors; actions by government agencies;
the impact of our collaborations on our development programs; the
potential timing of regulatory filings regarding our development
programs; the potential commercialization opportunities, including
value and market, for product candidates; our expectations
regarding our uses of capital, expenses, future accumulated deficit
and other 2018 financial results; and our ability to fund
operations through mid-2020. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs of future events, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: risks related to Intellia’s ability to
protect and maintain our intellectual property position; risks
related to the ability of our licensors to protect and maintain
their intellectual property position; uncertainties related to the
initiation and conduct of studies and other development
requirements for our product candidates; the risk that any one or
more of Intellia’s product candidates will not be successfully
developed and commercialized; the risk that the results of
preclinical studies will be predictive of future results in
connection with future studies; and the risk that Intellia’s
collaborations with Novartis or Regeneron or its other ex vivo
collaborations will not continue or will not be successful. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K filed with the Securities
and Exchange Commission, as well as discussions of potential risks,
uncertainties, and other important factors in Intellia’s other
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Intellia Therapeutics undertakes no duty to update this
information unless required by law.
Intellia Contacts:
Media:Jennifer Mound SmoterSenior Vice
PresidentExternal Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Lynnea OlivarezAssociate DirectorExternal Affairs &
Communications+1 956-330-1917lynnea.olivarez@intelliatx.com
Investors:Lindsey TrickettVice
PresidentInvestor Relations+1
857-285-6211lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024